Journal of cancer research & therapy最新文献_第3页

The first American cancer patient to receive dicycloplatin chemotherapy: A case report 美国首例接受双环铂化疗的癌症患者:一例报告

Journal of cancer research & therapy Pub Date : 2017-10-10 DOI: 10.14312/2052-4994.2017-11

J. Yu, M. Salkini, S. Jiao, T. Hogan, Y. Guo, Xiaobing Liang, B. Yang, L. Zhang, K. Gyure

{"title":"The first American cancer patient to receive dicycloplatin chemotherapy: A case report","authors":"J. Yu, M. Salkini, S. Jiao, T. Hogan, Y. Guo, Xiaobing Liang, B. Yang, L. Zhang, K. Gyure","doi":"10.14312/2052-4994.2017-11","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-11","url":null,"abstract":"Dicycloplatin (DCP), an effective platinum drug, was developed in China and approved by Chinese FDA in 2012. Its side effects are more bearable than those of cisplatin and carboplatin. The bladder cancer patient presented here was a 65-year-old Caucasian American male diagnosed at West Virginia University (WVU) Hospital in the USA and received 8 weeks of dicycloplatin chemotherapy in Beijing in 2016. He experienced moderate fatigue and aches but no vomiting or hair loss. His blood values decreased but remained in normal range. Quarterly cystoscopic follow-ups at WVU Hospital found no tumor recurrence. Studies of dicycloplatin-induced activation of the molecular signaling pathway in response to DNA damage, including investigation of Chk2, BRCA1 and p53, demonstrated that the signaling pathway is activated only in cancer cells, not in normal cells. Other in vitro data also indicate DCP mainly affects tumor cells, largely bypassing normal cells. These findings may explain DCP's more bearable side effects. Dicycloplatin may offer chemotherapeutic advantages over some platinum drugs in cancer treatment.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"41 1","pages":"56-60"},"PeriodicalIF":0.0,"publicationDate":"2017-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88072228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Can vascular endothelial growth factor C expression be of use in predicting surgical stage or prognosis in vulvar cancer 血管内皮生长因子C的表达能否用于预测外阴癌的手术分期或预后

Journal of cancer research & therapy Pub Date : 2017-09-01 DOI: 10.14312/2052-4994.2017-10

R. Nyberg, Marita Laurila, S. Staff, J. Mäenpää

{"title":"Can vascular endothelial growth factor C expression be of use in predicting surgical stage or prognosis in vulvar cancer","authors":"R. Nyberg, Marita Laurila, S. Staff, J. Mäenpää","doi":"10.14312/2052-4994.2017-10","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-10","url":null,"abstract":"Introduction: Nodal metastasis is a main prognostic factor in vulvar cancer. Increased vascular endothelial growth factor C (VEGF-C) expression has been associated with lymph node metastasis and poor prognosis in many cancers. The aim of this retrospective study was to investigate VEGF-C expression pattern in the invasive edge of vulvar cancer and in sentinel lymph node metastasis, and its association with the stage and prognosis. Methods: Tumor and sentinel lymph node samples from 44 patients were evaluated with immunohistochemistry, and the results were linked with the clinicopathological data. Results: Sixty-seven percent of primary tumors and 76% of sentinel lymph node metastases expressed VEFG-C. Positive VEGF-C expression of the primary tumor did not predict surgical Stage or sentinel lymph node involvement. The risk of relapse was not significantly higher with VEGF-C expressing tumors than with VEGF-C negative tumors (RR 2.55, 95% CI 0.66-9.90, p = 0.18). The risk of groin recurrence was significantly lower with VEGF-C positive than negative tumors (RR 0.36, 95% CI 0.16-0.79, p = 0.01). Survival was similar in both groups. No non-sentinel lymph node metastases were found in case of negative VEGF-C expression in the sentinel lymph node metastasis, whereas with positive VEGF-C expression they were found in 5/13 (38%) of cases. Conclusions: Tumoral VEGF-C expression was not associated with higher surgical Stage or poorer prognosis in vulvar cancer. However, absence of its expression in sentinel lymph node metastasis might indicate a low risk for non-sentinel lymph node metastases.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"66 1","pages":"50-55"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88523032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival? 新辅助厄洛替尼(特罗凯)治疗可切除非小细胞肺癌患者的皮疹:肿瘤反应和生存的预测因子?

Journal of cancer research & therapy Pub Date : 2017-08-01 DOI: 10.14312/2052-4994.2017-9

van Gool Mh, J. Burgers, K. Sikorska, E. Schaake, T. S. Aukema, H. Klomp

{"title":"Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?","authors":"van Gool Mh, J. Burgers, K. Sikorska, E. Schaake, T. S. Aukema, H. Klomp","doi":"10.14312/2052-4994.2017-9","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-9","url":null,"abstract":"Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell lung cancer (NSCLC). The aim of this analysis was to evaluate whether skin rash during treatment (as a biomarker) in a preoperative setting was related to response and survival. Methods: This study was designed as an open-label phase II trial (also known as M06NEL). Patients received preoperative erlotinib (Tarceva) 150 mg once daily for 3 weeks. Skin toxicity during treatment was analysed in relation to metabolic and histopathological response, overall survival (OS) and progression-free survival (PFS). Results: In total 59 patients (25 male, 34 female) were eligible for analysis. In 39 patients (66%) skin toxicity occurred. According to National Cancer Institute Common Toxicity Criteria (NCICTC), Grade 1 toxicity was seen in 15 patients (25%), Grade 2 in 19 patients (32%) and Grade 3 in five patients (8%). None of the patients showed skin toxicity Grade 4 and 5. The median follow up was 74 months. Thirty-six patients (61%) were alive at time of analysis. Twenty-seven patients (46%) showed disease progression during follow up. Hazard ratios (HR) indicated lower risk of death (HR = 0.66, 95%CI: 0.29 1.50) and progression (HR = 0.64, 0.30 1.36), although in this small group results were not significant. Skin rash did not adequately predict response. Conclusions: In this neoadjuvant setting with limited treatment time in patients with early stage NSCLC, skin rash was not associated with response and survival and cannot be used as an early biomarker.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"11 1","pages":"45-49"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87426418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Some aspects of cancer biomarkers and their clinical application in solid tumors – revisited 肿瘤生物标志物及其在实体瘤中的临床应用综述

Journal of cancer research & therapy Pub Date : 2017-07-03 DOI: 10.14312/2052-4994.2017-7

D. Isaac, J. Elayoubi, A. Almohammadi, Dimitrov Nv

引用次数: 0

Diagnostic problems and immune contexture in a case of cecal medullary carcinoma 盲肠髓样癌1例的诊断问题和免疫情况

Journal of cancer research & therapy Pub Date : 2017-07-03 DOI: 10.14312/2052-4994.2017-8

Sofia-Eleni Tzorakoleftheraki, T. Koletsa, C. Poulios, C. Kosmidis, A. Foka‐Karagiannopoulou, Tzioufa, I. Kostopoulos

{"title":"Diagnostic problems and immune contexture in a case of cecal medullary carcinoma","authors":"Sofia-Eleni Tzorakoleftheraki, T. Koletsa, C. Poulios, C. Kosmidis, A. Foka‐Karagiannopoulou, Tzioufa, I. Kostopoulos","doi":"10.14312/2052-4994.2017-8","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-8","url":null,"abstract":"Medullary carcinoma (MC) of the colon has recently been described as a separate variant of colorectal carcinoma, associated with microsatellite instability. Despite its morphological similarities to poorly differentiated adenocarcinomas (PDAs) and neuroendocrine carcinomas (NECs), the prognosis seems to be more favorable. A case of an adult female patient who presented with obstructive ileus due to a right-sided colon mass is reported. A specimen of right hemicolectomy was received and a large tumor was observed at the cecum. Tumor sections revealed a poorly differentiated carcinoma, without elements of intestinal differentiation on histologic or immunohistochemical examination. Further investigation lead to the diagnosis of MC of the cecum. The majority of lymphocytic populations of the microenvironment were granzyme B and T-cell intracellular antigen-1 (TIA-1) positive, with an abundant intraepithelial compartment. There were only a few Forkhead box P3(FOXP3) positive T-regulatory cells. It is emphasized that an undifferentiated large bowel carcinoma characterized by black-tan color on gross examination, expressing epithelial keratins and calretinin, proven to be microsatellite unstable with abundant intratumoral cytotoxic lymphocytes should be diagnosed as MC.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"36 1","pages":"40-44"},"PeriodicalIF":0.0,"publicationDate":"2017-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89195071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colitis and chronic bleeding in patients treated with dasatinib 达沙替尼治疗患者的结肠炎和慢性出血

Journal of cancer research & therapy Pub Date : 2017-06-02 DOI: 10.14312/2052-4994.2017-6

L. Campiotti, M. Suter, B. Elena, S. Uccella, Grandi Am, L. Guasti

引用次数: 1

The clinical and biological implications of the focal adhesion kinase pathway in ShenLingLan mediated suppression of cellular migration of ovarian cancer cells 参灵兰介导的局灶黏附激酶途径抑制卵巢癌细胞迁移的临床和生物学意义

Journal of cancer research & therapy Pub Date : 2017-06-02 DOI: 10.14312/2052-4994.2017-5

S. Owen, F. Ruge, Yunong Gao, Ying Yang, Jianli Hou, Jian Chen, J. Lane, Yongshan Gao, Hongtao Wang, Cong Wei, Yiling Wu, W. Jiang

{"title":"The clinical and biological implications of the focal adhesion kinase pathway in ShenLingLan mediated suppression of cellular migration of ovarian cancer cells","authors":"S. Owen, F. Ruge, Yunong Gao, Ying Yang, Jianli Hou, Jian Chen, J. Lane, Yongshan Gao, Hongtao Wang, Cong Wei, Yiling Wu, W. Jiang","doi":"10.14312/2052-4994.2017-5","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-5","url":null,"abstract":"The incidence of ovarian cancer in the UK has increased by almost twenty percent since the 1970’s and the majority of cases are not diagnosed until the late stages, when metastasis is more likely to have occurred. Focal Adhesion Kinase (FAK) is one of the key protein complexes which is integral to cell migration and has been linked to a variety of solid tumours. ShenLingLan (SLDM) is a traditional herbal medicine which has been formulated for the treatment of solid tumours. This study aimed to establish the impact of SLDM on FAK in ovarian cancer cells in vitro and transcript levels of FAK in an ovarian cancer cohort. FAK and paxillin phosphorylation events stimulated by SLDM treatment were identified using a Kinexus™ antibody based protein array. The impact of SLDM on cell attachment and migration was evaluated using Electric cell-substrate impedance sensing (ECIS), whilst the changes in focal adhesion complex localisation were assessed using immunofluorescence. In an ovarian cancer cohort, differences in FAK and paxillin transcript levels were assessed against key clinical parameters such as differentiation, stage and survival outcome. SLDM treatment of ovarian cancer cells in vitro resulted in the suppression of FAK and paxillin phosphorylation at several sites, which appeared to manifest as decreased cellular attachment and migration in a range of immortalised ovarian cancer cells. Increased FAK and paxillin transcript copies were observed in high grade and poorly differentiated ovarian tumours as well as in tumours from patients with ovarian cancer related incidence. SLDM has a profound effect on the migratory and adhesive properties of ovarian cancer cells, potentially via inhibitory effects on the activation of the FAK pathway, which is aberrant in clinical ovarian cancers.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"55 1","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2017-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88004627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epifluorescent imaging study of the effect of anti-diabetic drug metformin on colorectal cancer cell lines in vitro 抗糖尿病药物二甲双胍对体外结直肠癌细胞系影响的荧光成像研究

Journal of cancer research & therapy Pub Date : 2017-05-03 DOI: 10.14312/2052-4994.2017-4

P. Venkatasubramani, Chao Sima, Jianping Hua, M. Cypert, M. Bittner, A. Datta

引用次数: 0

Burden, quality of life and distress of the main caregiver in head and neck, cervix and rectal cancer patients 头颈、子宫颈癌和直肠癌患者主要照顾者的负担、生活质量和痛苦

Journal of cancer research & therapy Pub Date : 2017-03-03 DOI: 10.14312/2052-4994.2017-3

I. Miguel, A. Moreira, J. Freire

{"title":"Burden, quality of life and distress of the main caregiver in head and neck, cervix and rectal cancer patients","authors":"I. Miguel, A. Moreira, J. Freire","doi":"10.14312/2052-4994.2017-3","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-3","url":null,"abstract":"Purpose: Based on Portuguese experience, current practice does not focus sufficiently on the caregiver needs through caring of the cancer patient. Understanding the impact of different tumor types on caregiver burden, quality of life, and distress may help with organizing resources more efficiently to provide enhanced support for patients and caregivers. Methods: Ninety main caregivers of patients with cervix, rectal and head and neck cancer were interviewed at Instituto Português de Oncologia de Lisboa Francisco Gentil. The Portuguese versions of Zarit Burden Interview, Caregiver Quality of Life Index Cancer (CQOLC) Scale and the distress thermometer were used. Results: The majority of caregivers were female (76.7%), median age was 45.5years (20-79), 40% were spouses and 38.7% sons/daughters. Zarit Burden Interview average score was 25.2 ± 11.6, higher on head and neck cancer group. 59.5% of caregivers had moderate burden and no cases of severe burden. Mean quality of life score was 64.8 ± 15.8 which was lower in the head and neck group. Average distress score across the three groups was seven and rectal group presented a lower score than the other two groups. A subgroup analysis (gender, kinship relation, employment status and cohabitation before starting care) of caregivers characteristics showed no statistical differences. Conclusion: There were little differences in the experience of caring within caregivers based on the three different cancer groups, although caregivers of patients with head and neck cancer scored consistently worse in the three scales studied. More efforts should be taken to optimize coping strategies for these caregivers, as well as non-cohabitant and active caregivers, who had a worse caring experience.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"23 1","pages":"14-18"},"PeriodicalIF":0.0,"publicationDate":"2017-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78619172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb S-1、新型口服氟尿嘧啶和顺铂分疗程放化疗治疗IVb期食管癌远处转移

Journal of cancer research & therapy Pub Date : 2017-01-02 DOI: 10.14312/2052-4994.2017-1

H. Iwase, M. Shimada, N. Hirashima, N. Ryuge, Noboru Urata, Momoko Goto, T. Kondo, Daiki, Tanaka, Satoshi Unita, E. Kato

{"title":"Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb","authors":"H. Iwase, M. Shimada, N. Hirashima, N. Ryuge, Noboru Urata, Momoko Goto, T. Kondo, Daiki, Tanaka, Satoshi Unita, E. Kato","doi":"10.14312/2052-4994.2017-1","DOIUrl":"https://doi.org/10.14312/2052-4994.2017-1","url":null,"abstract":"Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Forty-one patients with distant oesophageal cancer metastasis and performance status 0 or 1 received split-course chemoradiotherapy with S-1 and cisplatin. All 41 patients were reviewed retrospectively. Chemoradiotherapy comprised two courses of 30-Gy radiotherapy over three weeks plus daily oral S-1 (70mg/m2/day) for two weeks and a 24 h cisplatin infusion (70mg/m2) on Day 8, with a two week interval between the two courses. Results: The most frequent adverse events (AEs) were grade 3 and 4 neutropenia (29.2%), thrombocytopenia (9.8%), and anaemia (7.3%). Non-haematological AEs were generally mild. AEs in the initial course of chemoradiotherapy remitted during the second interval week. Overall, the complete response rate was 22.0% and endoscopic complete response rate for primary lesion was 65.9%. Thirty-one patients (75.6%) became asymptomatic and regained normal swallowing function. The overall median survival time was 12 months. Conclusion: This retrospective investigation showed that split-course chemoradiotherapy with S-1 and cisplatin had an encouraging safety profile together with good efficacy. Potentially, this regimen may become a standard for distant metastasis of oesophageal cancer stage IVb.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"8 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85202709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0